Companies › Atossa Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| (Z)-endoxifen Selective estrogen receptor modulator (SERM) | ESR1 | Phase 2 | Breast Neoplasms | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05607004 | (Z)-endoxifen | Phase 2 | Breast Neoplasms | Oncology | Nov 2026 |
Cash of $21m on 2026-09-30; operating cash outflow about $33m a year; runway about 7 months at that burn, to May 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
LeonaBio Shanghai Best-Link Bioscience Dogwood Therapeutics Curis Processa Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.